Kaiyang Ding

机构：University of Science and Technology of China, Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital of Henan University of Science and Technology, First Affiliated Hospital of Anhui Medical University, Hefei First People's Hospital · ORCID：0000-0002-5521-3519

发表论文 144 篇 · 总被引 1166 次 · h-index 18

代表论文

• Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma (2024 · JAMA Oncology · 被引 21)
• Extranodal diffuse large B‐cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study (2025 · 癌症：英文版 · 被引 14)
• Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma (2025 · Blood Cancer Journal · 被引 8)
• Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma (2025 · BMC Cancer · 被引 5)
• Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 3)
• Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trial (2024 · European Journal of Cancer · 被引 3)